Misonix Inc. (NSDQ: MSON) posted second-quarter sales of $3.4 million for the three months ended Dec. 31, 2009, down 31 percent compared with $4.9 million during the same period in fiscal 2009. Net losses were $367,000, compared with net income of $194,000 during Q2 2009:
Misonix Inc. (NASQ:MSON) struck a deal to sell its SonaStar and BoneScalpel surgical tools in Chile.
Officials with Farmingdale, N.Y.-based Misonix said the new distribution agreement with Neuromed Chile SA coincides with a renewed focus by the ultrasound device manufacturer on the Latin American market.
“We are particularly pleased that they will be distributing two of our key products through their well established surgical products organization,” Misonix Chief Executive Michael McManus said in prepared remarks.